ARCHIVES

Gleevec Maintenance Therapy Showed Significant Benefits At Three Years in Phase III Trial

This article is from The Cancer Letter archive.

Vol. 35 No. 4 | April 27, 2012

Download PDF Visit The Full Archive

Related Articles

NSABP Trial Finds Raloxifene Equivalent To Tamoxifen For Cancer Risk Reduction

April 28, 2006

DeVita Denies NCI Broke Faith With Communities On CHOP Awards, Says Total Of 30 “Not Absolute”

August 15, 1980

In Brief: NCI, EPA Award contract For Farmers study To Iowa, North Carolina; NIAID’s Hoth to Resign

January 29, 1993

Cancer Incidence Rates Climb In HIV-Positive Female Populations

April 27, 2012

Aromasin Approved By FDA For ER+ Early Breast Cancer

October 28, 2005

In Brief: Metcalf, Sachs, Nowell, Rowley, Elkind Win 1989 GM Award; Ray Morrison Retires

June 16, 1989